Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Weak Q2 Sales Highlight Dependence On The Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales in almost all of Pfizer's key pharmaceutical businesses fell in the second quarter, sending the company's stock price down 4.5%.
Advertisement

Related Content

Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out
Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out
Remoxy's "Complete Response" Letter Has No Clear Culprit But Many Suspects

Topics

Advertisement
UsernamePublicRestriction

Register

PS072669

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel